Published: 12 July 2022
Author(s): Shu Li, Fen Li, Ni Mao, Jia Wang, Xi Xie
Section: Letter to the Editor
We appreciate the opportunity to reply to the Letter to the Editor by Dimosiari and colleagues [1], commenting on our work [2]. We concur with them that the cardiovascular disease (CVD) risk of Janus kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS) deserves attention.
